使用微信扫一扫分享到朋友圈
尊敬的投资者们,
我们诚挚邀请您参加将于2025年8月29日上午10:00召开的维亚生物2025年中期业绩发布会。
点击“立刻报名”通过审核后,本次会议的参会信息将发送至您的报名邮箱。
Dr. Chen (Cheney) Mao is the Chairman, CEO of our Company. He is primarily responsible for the overall strategic planning and business development of the Group. Dr. Mao has over 20 years of experience in the CRO industry. Dr. Mao obtained his bachelor’s and master’s degree from Fudan University in the PRC, and obtained his Ph.D. degree in biochemistry from Cornell University in the U.S. After graduation, he served as a director of the Department of Structural Biology of Parker Hughes Institute. He also served as a reviewer on the U.S. National Institutes of Health Review Panel ZRG1 AARR-1(50) in relation to AIDS-related structural biology projects grants.
Dr. Ren joined Viva Biotech (Shanghai) Co., Ltd. in 2009, mainly responsible for the overall management of the company CRO business. Prior to joining Viva Biotech, Dr. Ren has worked over ten years in Warner-Lambert Pharmaceuticals and Pfizer Global Research and Development served as a principle scientist and project leader since 1998, focusing on new drug discovery diabetes, obesity and inflammatory diseases. Dr. Ren received his Ph.D. in Animal Science at Michigan State University, and conducted Post-doctor research in Biochemistry at MSU. He has published about 20 research papers in international scientific journals.
Bachelor degree in Economics and Management, Shanghai University of Finance and Economics. More than 15 years of working experience in financial management and capital market. He has been engaged in Corporate Financing and M&A related consulting work in PwC and Hong Kong Avista Group.
招商医药 梁广楷/许菲菲/肖笑园
广发医药 罗佳荣/田鑫
中信医药 陈竹/韩世通/朱家成
国元国际 林兴秋
国泰海通 余文心/周航/陈铭/吴晗
中金医药 张琎/俞波/吴婉桦
兴证医药 孙媛媛/黄翰漾/乔波耀
中泰医药 祝嘉琦/崔少煜